- Home
- EOLS
EOLS
Evolus Inc.
as 05-30-2025 4:00pm EST
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $23.75 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.67 - $17.82 | Next Earning Date: | 05-07-2025 |
| Revenue: | $275,463,000 | Revenue Growth: | 25.38% |
| Revenue Growth (this year): | 33.27% | Revenue Growth (next year): | 32.31% |
Stock Insider Trading Activity of Evolus Inc. (EOLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Beaver Sandra | EOLS | Chief Financial Officer | May 13 '25 | Sell | $10.02 | 6,494 | $65,069.88 | 167,089 | |
| MOATAZEDI DAVID | EOLS | See Remarks | May 12 '25 | Sell | $9.87 | 15,787 | $155,756.12 | 492,832 | |
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 27 '25 | Sell | $12.40 | 6,251 | $77,512.40 | 492,832 | |
| Beaver Sandra | EOLS | Chief Financial Officer | Mar 18 '25 | Sell | $13.26 | 8,996 | $119,242.88 | 167,089 | |
| Yamagishi-Dressler Tomoko | EOLS | Chief Marketing Officer | Mar 18 '25 | Sell | $13.26 | 4,536 | $60,124.68 | 95,671 | |
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 18 '25 | Sell | $13.26 | 103,376 | $1,370,248.88 | 492,832 | |
| Avelar Rui | EOLS | See Remarks | Mar 18 '25 | Sell | $13.26 | 27,904 | $369,867.52 | 362,467 | |
| Parschauer Karah Herdman | EOLS | Director | Mar 12 '25 | Sell | $12.99 | 12,888 | $167,465.38 | 32,183 |
Latest Evolus Inc. News
EOLS Breaking Stock News: Dive into EOLS Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Evolus CFO Sandra Beaver Resigns
Business Wire
4 days ago
Evolus Announces Departure of its Chief Financial Officer
Business Wire
10 days ago
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
Business Wire
15 days ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
19 days ago
Evolus, Inc. (EOLS): A Bull Case Theory
Simply Wall St.
22 days ago
Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Simply Wall St.
23 days ago
Evolus First Quarter 2025 Earnings: Misses Expectations
Thomson Reuters StreetEvents
24 days ago
Q1 2025 Evolus Inc Earnings Call
Compare EOLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EOLS Evolus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.